by Vivian Yang
In the lead-up to the 35th World AIDS Day on December 1, JD Health joined hands with UNAIDS China to carry out equipment donations, an expert’s livestream and dedicated promotion of anti-AIDS services via its platforms.
Under JD Health’s coordination, more than 10,000 pieces of HIV testing tools and protection kits were donated to Beijing Love Without Borders, an NGO that supports local communities’ work to end AIDS. Eight companies including Gu Xiao Jia, Wondfo, Accu News, Wellday, Jissbon, Leeswell, AiD, and LifeStyles participated in the donation activity.
At the same time, JD Health set up a theme portal on its App from November 30 to December 2 to promote public awareness of HIV/AIDS. On December 1, Dr. Wu Zunyou, the chief epidemiologist of the Chinese Center for Disease Control & Prevention was invited for a livestream on the platform to convey AIDS-related knowledge.
During the sharing session, Dr. Wu pointed out that ordering HIV testing products and medications through e-commerce and receiving online medical consultations and psychological counseling via telemedicine methods at anytime and anywhere can significantly enhance people’s access to help for AIDS prevention and treatment, while offering greater relief and privacy protection.
Products for both Pre-Exposure Prophylaxis (PrEP) and Post-Exposure Prophylaxis (PEP) with clear guidance can be easily accessed on JD Health’s App, and medicines are delivered to users’ doorsteps in a timely manner, along with dedicated telemedicine consultation services from physicians for customized support.
According to data from China’s National Health Committee, there were 129,000 new positive HIV cases found in China in 2021, with 97.9 percent caused by sexual transmission, which continue to be the main challenge for society in fighting the disease.
(vivian.yang@jd.com)
Sep 8, 2026| JD Health
Beyond the Chatbot: How JD Health Is Bringing AI Into Doctors’ Everyday Work
A doctor reviewing a complex case may need to search through medical literature, check the latest clinical guidelines, assess drug interactions, interpret test results and bring together years of patient information, often under significant time pressure.
This is where Zhiyi (知医) comes in. Developed by JINGDONG Health (also known as JD Health), Zhiyi is an evidence-based AI assistant built specifically for healthcare professionals. Its Chinese name fittingly brings together the ideas of “professional knowledge” (知) and “doctor” (医).
Launched in January 2026, Zhiyi brings AI into the everyday workflow of doctors in China, supporting clinical decision-making, medical research, patient management and other professional tasks. It has integrated more than 50 million medical papers, clinical guidelines and authoritative journal resources, together with information from more than 160,000 pharmaceutical product instructions. The platform has already served over one million doctors and supported more than 20 million clinical decision-making interactions.

From Finding Information to Understanding the Evidence
Searching for medical information is one thing. Turning it into useful evidence for a particular patient or clinical situation is much harder.
Zhiyi is designed to help doctors move beyond simple search. Its Deep Thinking mode can break down complex questions, assess different levels of evidence and provide structured references for doctors to consider, including in cases involving multiple conditions or medications.
A good example is oncology. Zhiyi has integrated the China Anti-Cancer Association (CACA) Guidelines for Holistic Integrative Management of Cancer, which cover 29 cancer types and 72 diagnostic and treatment technologies. By making this body of specialist knowledge searchable and actionable through AI, Zhiyi can help doctors access relevant evidence when they need it, rather than requiring them to navigate lengthy reference materials separately.
Zhiyi also offers more than 200 medical calculators, covering areas such as disease assessment, risk stratification, medication dosage and cardiovascular risk, with AI providing evidence-based interpretation of the results. Its research assistant extends these capabilities into academic work, supporting literature reviews, patient education materials and presentations.
The aim is simple: reduce the time doctors spend navigating information so they can focus more of their expertise on understanding the patient and making clinical decisions.
Making AI Fit the Way Doctors Actually Work
Clinical information rarely arrives as a perfectly structured prompt.
It may be a laboratory report, prescription, medical image, PDF document or information collected across previous consultations. Zhiyi’s multimodal capabilities allow doctors to upload and analyze different types of clinical materials, reducing the need for manual entry and page-by-page review.
More importantly, Zhiyi is designed to show doctors where its conclusions come from. Its dynamic evidence-location capability can identify the original text supporting a clinical point, allowing doctors to trace AI-generated information back to the underlying evidence.
That distinction matters in healthcare. A useful medical AI assistant should not simply produce an answer; it should help a professional understand the evidence behind it.

When “Sounds Right” Isn’t Good Enough
Generative AI can produce convincing answers. In medicine, however, convincing is very different from reliable.
JD Health has therefore built dedicated evaluation systems around Zhiyi. Its MedScope framework evaluates AI outputs across evidence quality, content accuracy, appropriate expression and practical usefulness, supported by evaluation sets spanning 46 major clinical specialties.
A separate MedSafety framework evaluates 26 categories of high-risk medical scenarios, including medication contraindications and complication warnings. High-risk outputs that cross defined safety boundaries do not pass the evaluation.
This reflects an important principle behind JD Health’s approach: AI is there to support medical professionals, not to replace their experience, judgment or responsibility.
One AI Foundation, Different Healthcare Supports
Zhiyi is part of a broader AI healthcare architecture JD Health has been developing.
Underneath it is Jingyi Qianxun (京医千询), JD Health’s proprietary medical large language model. Rather than positioning the model itself as the final product, JD Health is applying its capabilities to specific healthcare workflows, including evidence retrieval, clinical support, patient follow-up and medical research. Zhiyi is one example of how that underlying AI capability is translated into a practical professional tool.
On the patient-facing side, Dawei (大为), JD Health’s AI doctor, applies AI to another part of the healthcare journey. JD Health has also launched more than 1,500 AI agents based on specialist doctors, alongside solutions developed for hospitals and specific disease areas.
Together, they illustrate a broader strategy: rather than building one AI assistant for every healthcare problem, JD Health is developing specialized AI tools around the needs of different users and healthcare scenarios.

Taking Medical AI Beyond Major Hospitals
Perhaps one of the most meaningful tests of medical AI is whether it can make high-quality tools more widely accessible.
In August, JD Health formed a strategic partnership with PICA Health (Yunqueyi), one of China’s largest digital platforms serving primary-care doctors. Zhiyi has been integrated into the PICA Health app, making its upgraded capabilities, including Deep Thinking, medical calculators and research assistance, available free of charge to the platform’s registered primary-care doctors serving. PICA Health connects around three million registered primary-care doctors serving China’s grassroots.
The significance is not simply putting AI into more hands. A doctor working in a smaller community can use the same AI tool to access medical literature, clinical guidelines and evidence-based decision support that would otherwise be more difficult or time-consuming to obtain.
And this is where JD Health brings another capability into the picture: supply chain infrastructure.
JD Health’s pharmaceutical supply chain reaches more than one million villages in China, while same- or next-day delivery coverage has reached 87.1% across county-level areas covered by its network.
This creates an interesting connection between medical intelligence and healthcare access: AI can help doctors find and interpret the right evidence, while supply chain capabilities can help turn a clinical decision into access to the medicines and healthcare products patients need.

Building AI Around Healthcare, Not Healthcare Around AI
There is no shortage of discussion about how powerful the next generation of medical AI models will become. JD Health’s experience with Zhiyi suggests that model capability is only part of the equation.
Healthcare AI also needs trusted medical evidence, safety mechanisms, integration into real clinical workflows and a way to reach the doctors and patients who can benefit from it.
That is why Zhiyi is particularly illustrative of JD Health’s broader approach. The technology begins with a medical large language model, but extends into authoritative resources such as the CACA Guidelines, professional tools for doctors, partnerships such as PICA Health, patient-facing services such as Dawei, and JD Health’s wider healthcare and supply chain infrastructure.
Doctors’ experience, judgment and responsibility remain at the center. The role of AI is to help those capabilities go further by making trusted knowledge easier to reach, complex information easier to navigate and everyday clinical work more efficient.
The more meaningful question for healthcare may therefore be not whether AI can become a doctor, but how AI can help every doctor do more for every patient.
(vivian.yang@jd.com)
Aug 28, 2026| ESG, JD Industrials
AI-Powered, ESG-Embedded Industrial Supply Chain Innovation Earns JINGDONG Industrials 2026 Sedex Technoical Innovation Award
BEIJING, 27 August 2026 — JINGDONG Industrials, a leading industrial supply chain technology and service provider under JD.com, has won the Technical Innovation Award among the 2026 Sedex Supply Chain Awards, recognising its use of AI and technical solutions to embed ESG capabilities into industrial supply chain operations. The company was also nominated for the Social Impact Award.
JINGDONG Industrials was the only industrial supply chain technology and service company to receive the Technical Innovation Award this year during Sedex China Annual Conference. Sedex is one of the world’s leading platforms for responsible and sustainable supply chains, used by businesses globally to assess, manage and improve environmental, social and ethical performance across their value chains.

From Supply-Demand Matching to Carbon Management: AI Tackles Real Supply Chain Challenges
Industrial supply chains often face a common set of challenges: mismatches between supply and demand that create resource waste, fragmented ESG data that is difficult to manage, and compliance risks that can be hard to identify early.
JINGDONG Industrials addresses these challenges by combining its Taipu digital-physically integrated industrial supply chain solution with JoyIndustrial, its proprietary industrial supply chain large language model. Built on data covering more than 97.7 million industrial product SKUs and experience across over 40 industrial sectors, JoyIndustrial uses a multi-agent architecture to support intelligent decision-making across industrial supply chain scenarios.
Together, these capabilities support three key areas: intelligent supply-demand matching, end-to-end carbon management, and AI-enabled compliance and risk management. The approach is designed to embed ESG into day-to-day supply chain operations, rather than treating sustainability as a standalone reporting exercise.

1,780 Tonnes of Carbon Reduction: Turning Technology into Measurable Impact
The impact is already measurable. Through smarter supply-demand matching and logistics optimisation, JINGDONG Industrials helps customers reduce unnecessary transportation and resource waste.
The company has also partnered with suppliers to scale the use of PCR (post-consumer recycled) packaging through its technology solutions. From May to December 2025, these initiatives contributed to an estimated 1,780 tonnes of carbon reduction, with the underlying technologies now adopted across more than 3,000 enterprise customers.
On compliance, its AI-powered risk management engine covers 100% of identified risk scenarios and achieves a reported 96% risk-interception rate, helping customers detect supplier compliance risks earlier and strengthen quality management across the supply chain.
“The recognition from Sedex reinforces our conviction that digitalisation and sustainability must advance in tandem across the industrial supply chain,” said a spokesperson for JINGDONG Industrials. “Our focus is on turning data and AI into practical tools that help businesses improve efficiency, manage risk, and make more informed sustainability decisions.”

Building a More Responsible Industrial Supply Chain Ecosystem
As of the first half of 2026, JINGDONG Industrials served approximately 13,000 key enterprise customers, including 60% of China’s Fortune 500 companies and more than 40% of the Global Fortune 500 companies operating in China.
Its responsible sourcing practices also extend upstream. The company has established lifecycle compliance management covering approximately 230,000 suppliers, with all onboarded suppliers required to sign anti-commercial-bribery agreements. JINGDONG Industrials has also obtained international certifications, including ISO 45001, ISO 27001, and ISO 27701.
These capabilities are becoming increasingly relevant as industrial companies navigate ever more complex sourcing, sustainability, and compliance requirements. JINGDONG Industrials is expanding its international presence across Europe, Southeast Asia, the Middle East, and Latin America, extending its digital procurement and supply chain capabilities to more global customers and partners.
The company continues to work with upstream manufacturers on product carbon-footprint management, giving customers more quantifiable data to support lower-carbon procurement decisions. By embedding sustainability into everyday sourcing and supply chain operations, JINGDONG Industrials aims to make responsible procurement more practical and scalable across the industrial ecosystem.
About JINGDONG Industrials
JINGDONG Industrials (HKEX: 7618) is a leading industrial supply chain technology and service provider under JD.com, dedicated to transforming how enterprises procure and manage industrial products.
Leveraging JD.com’s supply chain, logistics, and digital capabilities, JINGDONG Industrials provides digital procurement and supply chain solutions across a broad range of industrial products, including MRO (maintenance, repair, and operations), industrial materials, tools, and equipment. Its customers span industries including manufacturing, energy, and construction.
JINGDONG Industrials is also expanding its international operations across Europe, Southeast Asia, the Middle East, and Latin America, working with customers and partners to build more efficient, resilient, and responsible industrial supply chains.
(vivian.yang@jd.com)
Jun 16, 2026
Redefining Growth: Inside JD.com’s 2025 ESG Journey
Stay up to date on the latest news from JD.com
Enter your email address to subscribe to this blog and receive notifications of new posts by email.

JD Logistics Launches Its Second Warehouse in Dubai



